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Brain atrophy and lesion load in a
large population of patients with
multiple sclerosis
G. Tedeschi, MD; L. Lavorgna, MD; P. Russo, MD, PhD; A. Prinster, PhD; D. Dinacci, MD;
G. Savettieri, MD; A. Quattrone, MD; P. Livrea, MD; C. Messina, MD; A. Reggio, MD; V. Bresciamorra, MD;
G. Orefice, MD; M. Paciello, MD; A. Brunetti, MD; G. Coniglio, MD; S. Bonavita, MD; A. Di Costanzo, MD;
A. Bellacosa, MD; P. Valentino, MD; M. Quarantelli, MD; F. Patti, MD; G. Salemi, MD; E. Cammarata, MD;
I.L. Simone, MD; M. Salvatore, MD; V. Bonavita, MD; and B. Alfano, PhD
Abstract—Objective: To measure white matter (WM) and gray matter (GM) atrophy and lesion load in a large population
of patients with multiple sclerosis (MS) using a fully automated, operator-independent, multiparametric segmentation
method. Methods: The study population consisted of 597 patients with MS and 104 control subjects. The MRI parameters
were abnormal WM fraction (AWM-f), global WM-f (gWM-f), and GM fraction (GM-f). Results: Significant differences
between patients with MS and control subjects included higher AWM-f and reduced gWM-f and GM-f. MRI data showed
significant differences between patients with relapsing–remitting and secondary progressive forms of MS. Significant
correlations between MRI parameters and between MRI and clinical data were found. Conclusions: Patients with multiple
sclerosis have significant atrophy of both white matter (WM) and gray matter (GM); secondary progressive patients have
significantly more atrophy of both WM and GM than do relapsing–remitting patients and a significantly higher lesion load
(abnormal WM fraction); lesion load is related to both WM and even more to GM atrophy; lesion load and WM and GM
atrophy are significantly related to Expanded Disability Status Scale score and age at onset (suggesting that the younger
the age at disease onset, the worse the lesion load and brain atrophy); and GM atrophy is the most significant MRI
variable in determining the final disability.
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The histopathologic features of multiple sclerosis
(MS) include multiple foci of inflammation and de-
myelination as well as potentially substantial de-
structive or degenerative changes in both white
matter (WM) and gray matter (GM).1-4 Recently, ad-
vanced MRI techniques have demonstrated that
even early in the course of the disease, there is neu-
ronal and axonal damage in the lesions and beyond,
thus leading to the concept of the so-called normal-
appearing WM (NAWM).5,6 Furthermore, MRI data
have led to the hypothesis that progression of the
disease, up to a stage of no return, is dependent on
the cumulative effect of axonal damage,7 which may
ultimately result in MRI-visible brain atrophy.8
There has been an active search for sensitive MRI
methods to measure brain atrophy and other objec-
tive parameters of tissue damage. Up to now, various
approaches have been developed to measure brain
atrophy. In an effort to obtain reliable, reproducible,
and objective measurements of brain atrophy,
MRI methods have evolved from semiautomated,
operator-dependent segmentation techniques to au-
tomated, operator-independent ones.8,9 A few studies
have assessed volume changes in both WM and GM
using a largely automated approach,10-14 but none
has been conducted measuring both WM and GM
atrophy as well as lesion load on large numbers of
patients with MS. Although previous studies10-14 pro-
vided consistent evidence that brain atrophy is a
relevant feature of MS, the differential involvement
of WM and GM in patients with different disease
courses as well as the intercorrelations between WM
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and GM atrophy and lesion load and the correlations
between WM and GM atrophy and clinical features
have been only partially defined.
We sought to measure WM and GM atrophy and
lesion load in a large population of patients with MS
using a fully automated, operator-independent, mul-
tiparametric segmentation method and to investi-
gate the intercorrelations between WM and GM
atrophy and lesion load and the correlations between
clinical and MRI data. This was accomplished by
organizing a multicenter study, in which an MRI
machine housed in a truck traveled to different
locations to perform the same MRI protocol in all
patients.
Methods. The study design was cross-sectional. During a pre-
defined 6-month time window, all consecutive patients with MS,
on the basis of a prescheduled visit, and all consecutive 20- to
50-year-old sex-matched healthy volunteers were included. Pa-
tients with definite MS15 were recruited from the MS outpatient
clinics of seven university hospitals (Second University of Naples,
University “Federico II” of Naples, and Universities of Bari, Ca-
tanzaro, Messina, Catania, and Palermo) and the regional hospi-
tal of Potenza. Because these centers supply interferons (IFNs)
and other immunomodulators to patients with MS, and consider-
ing the high frequency of treatment in Italian patients with MS, it
is likely that the patients of our sample are representative of the
general MS population. Another selection bias may be due to the
number of patients who disagreed to participate to the study.
Indeed, the percentage of refusals was very low (5%).
All enrolled subjects were examined on the same day as the
MRI session. Criteria for excluding patients were ongoing clinical
relapse, other major medical illnesses, history of substance abuse,
and corticosteroid treatment within 12 weeks of the start of the
study. Criteria for excluding volunteers were neurologic disorders,
major medical illnesses, history of substance abuse, and current
drug treatment.
Seven hundred thirty-three subjects took part in the study: 629
patients with MS and 104 control subjects. Thirty-two patients
with MS were not included in the final analysis because they did
not complete the MRI exam or because of motion artifacts, so the
study results are based on 597 patients with MS and 104 control
subjects. The protocol was approved by local ethics committees.
All participants gave written informed consent.
MRI studies. The same MRI protocol was performed in all
subjects using the same MRI machine (1.0 T Genesys Signa; GE
Medical Systems, Milwaukee, WI). For each study, two inter-
leaved sets of 15 slices (4 mm thick) covering the entire brain were
acquired, using for each set two conventional spin echo sequences
(repetition time/echo time [TR/TE] 600/15 milliseconds), two aver-
ages; TR/TE 2,300/15 milliseconds, 90-millisecond dual-echo se-
quence, one average; both with 90° flip angle and 256  192
matrix. All the studies were segmented using a multispectral fully
automated method, based on relaxometric characterization of
brain tissues.16,17 The program furnishes complete sets of multifea-
ture images (R1 [1/T1], R2 [ 1/T2], proton density [N(H)-
based]) and segmented images and calculates the volumes of the
following intracranial tissues: CSF, GM, NAWM, abnormal WM
(AWM), and global WM (gWM; calculated as the sum of NAWM
and AWM). To normalize for head size variability, the volumes of
intracranial tissues were expressed as fractions (f) of the intracra-
nial volume, which were calculated for each subject as the sum of
all intracranial tissues. AWM-f is a measure of lesion load as
determined by the R1, R2, and N(H) information and morphologic
characteristics, the reduction of gWM-f indicates WM atrophy,
and the reduction of GM-f indicates GM atrophy. Figure 1 shows a
transverse slice of a patient with MS and depicts the major steps
of the multiparametric method that, starting with a proton
density-weighted image and a T2-weighted image, produces the
corresponding multiparametric image and the resulting seg-
mented image. In the latter image, the WM is represented by
white, the GM by gray, the CSF by blue, and the lesions by yellow.
For each study, a couple of interactive interslice movies of both
multifeature and segmented images were produced, and two neu-
roimaging experts reviewed them (for a maximum of 2 minutes) to
detect motion artifacts and segmentation errors due to the imper-
fect separation of nasal mucosa and vitreous humor from brain
tissue. In 111 studies (15.8%) in which nasal mucosa or vitreous
humor was erroneously classified as GM or CSF, manual cuts of
thin connections between intra- and extracerebral tissues in the
multifeature image set were performed, allowing the program to
outcome correct segmentation and volumetry.
Two improvements have been made to the previously pub-
lished descriptions of the segmentation method: Thanks to better
radiofrequency homogeneity of the head coil used, no R1 correc-
tion along the z axis was performed and, a multi-Gaussian fitting
of R1 voxel distribution was introduced to eliminate the previ-
ously observed slight underestimation of GM-f in the presence of
high AWM-f.
Statistics. MRI volume data were presented as means and
95% CI. The mean MRI parameters of all subjects were adjusted
by age, gender, and education using a linear regression model.
Before regression analysis, individual variables were checked for
skewness and the presence of outliers. Post-hoc comparisons be-
tween patient and control groups were conducted with Bonferroni
test. The univariate relationships between MRI volume fractions
were estimated using Pearson correlation coefficients.
To evaluate the relevance of demographic, clinical, and thera-
peutic variables on each brain volume fraction, several multivari-
ate analyses were performed. These analyses were performed
using a general regression model with a forward stepwise proce-
dure to evaluate the effect of categorical predictors (gender: male
vs female; MS course: relapsing–remitting [RR] vs secondary pro-
gressive [SP] vs primary progressive [PP]; type of MS onset: mono-
symptomatic vs polysymptomatic; type of therapy: IFN  vs other
therapy vs withdrawal from IFN vs never treated) and continu-
ous predictors (age, years of school attended, age at disease onset,
disease duration, Expanded Disability Status Scale [EDSS] score,
Figure 1. Transverse slice of patient with multiple sclero-
sis. (A) Proton density-weighted image; (B) T2-weighted
image; (C) corresponding multiparametric image; (D) re-
sulting segmented image. In the segmented image, the
white matter is represented by white, the gray matter by
gray, the CSF by blue, and the lesions by yellow.
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relapse rate) on a continuous dependent variable (i.e., each MRI
volume fraction). Regression models were set with the categorical
and continuous predictors previously indicated, and the forward
stepwise procedure was applied. Thus, after the first step, the
regression equation was composed of those predictors reaching
specific thresholds of F and p values (for predictor inclusion: F  1
and p  0.05; for exclusion: F  1 and p  0.05). After several
iterations, the final equation was composed only by those vari-
ables responding to the entry/removal criteria. The B value in the
final regression equation expresses the percentage variation of the
brain fraction volume on the whole volume for a unit variation of
the predictor. The  values are standardized coefficients that pro-
vide a comparable weight of each predictor with each other in-
cluded in the regression equation.
Finally, to evaluate the relative contribution of clinical, socio-
demographic, and MRI-related variables to MS outcomes, further
multivariate analyses were performed. These general regression
models identified the predictors of both disability (as expressed by
the EDSS score) and relapse rate, including the following predic-
tors: gender, years of school attended, age at disease onset, dis-
ease duration, MS course, MS onset, therapy, and brain volume
fractions. Analogously to previous models, these regressions were
also set applying the forward stepwise procedure.
Results are presented as the b value (SE) and the  coefficient
and its 95% CI. All statistical analyses were performed using
Statistica version 6.0 (Statsoft s.r.l., Italy) and Confidence Inter-
val Analysis for Windows.18 p values of 0.05 were considered
significant.
Results. The study population of patients with MS con-
sisted of 383 women and 214 men (women/men ratio  1.8)
ages 16 to 68 years (mean  SD 38.1  10.3 years). Their
age at disease onset was 10 to 61 years (28.4  9.1 years),
and their EDSS scores19 were 0 to 8.5 points (2.99  1.7
points). Disease duration was 9.73  7.26 years, and num-
ber of relapses in the previous 2 years was 1.04  1.3. The
clinical course was RR in 427 (71.5%), SP in 140 (23.5%),
and PP in 30 (5.0%). EDSS score was 3.5 in 452 patients
(88.3% RR, 7.5% SP, 4.2% PP), between 4 and 6 in 110
patients (22.7% RR, 60.9% SP, 16.4% PP), and 6.5 in 35
patients (57.1% SP, 42.9% PP).
Measurements of segmented MRI volumes in the pa-
tients with MS and controls are presented in table 1. In
patients with MS, the mean value of AWM-f was 1.4%
(95% CI 1.3 to 1.5), which corresponds to a lesion load of
about 17 cm3 in an average brain of 1,200 cm3. gWM-f was
(p  0.001) reduced in patients with MS by 1.3% (95% CI
0.5 to 2.1), which corresponds to a volume loss of about
15.6 cm3 in an average brain of 1,200 cm3.
GM-f was reduced (p  0.001) in patients with MS by
2.1% (95% CI 1.4 to 2.8), which corresponds to a volume
loss of about 25 cm3 in an average brain of 1,200 cm3.
Table 2 shows the comparisons of segmented MRI vol-
umes in patients with MS with different disease courses.
Between-group comparisons evidenced significant differ-
ences of MRI parameters only in RR patients with respect
to SP patients. Both gWM-f and GM-f were significantly
lower in the SP group than in the RR group. The magni-
tude of the gWM-f reduction was similar to that of GM-f,
being 1.4% (95% CI 0.8 to 2.0) for both. Furthermore,
AWM-f was significantly higher in the SP group than in
the RR group [0.7%; 95% CI 0.3 to 1.1).
The intercorrelations between segmented MRI fractions
are presented in table E-1 on the Neurology Web site at
www.neurology.org. Lesion load (AWM-f) was inversely
correlated with all other MRI fractions; however, a stron-
ger relationship was found with GM-f (r  0.58) than
with gWM-f (r  0.35) (p  0.001, for Pearson r coeffi-
cient comparison).
The multivariate correlations of MRI fractions with
clinical features are reported in table E-2. Three signifi-
cant predictors of lesion load (AWM-f) were obtained:
EDSS, age at disease onset, and drug treatment (IFN vs
never treated). The strongest predictor was disability: A
1-point increase in the EDSS score corresponded to about a
0.24% increase of AWM-f (2.9 cm3 for an average brain of
1,200 cm3). Furthermore, a 0.15% increase of AWM-f was
found for each 5 years earlier that the MS had its onset.
IFN-treated patients had a higher lesion load (adjusted
mean of 1.6%; 95% CI 1.4 to 1.7) than did patients who had
never been treated (1.2%; 95% CI 1.0 to 1.5, p  0.008).
With regard to WM atrophy (gWM-f), the strongest pre-
dictor was age at onset followed by disability: A 0.45%
decrease of gWM-f was found for each 5 years earlier of MS
onset. Furthermore, a 1-point increase in the EDSS score
corresponded to about a 0.41% decrease of gWM-f (about 5
cm3 for an average brain of 1,200 cm3).
Table 1 Comparisons between control subjects and patients with
MS for adjusted* MR volumes (as % of whole-brain volume)
Mean (95% CI)
p Value
Patients with
MS, n  597
Controls,
n  104
AWM-f 1.4 (1.3–1.5) 0.1 (0.0–0.4) 0.001
gWM-f 33.8 (33.5–34.1) 35.1 (34.4–35.7) 0.001
GM-f 51.0 (50.7–51.2) 53.1 (52.5–53.7) 0.001
* Adjusted for age, sex, and education.
MS  multiple sclerosis; AWM-f  abnormal white matter frac-
tion; gWM-f  global white matter fraction; GM-f  gray matter
fraction.
Table 2 Comparisons of adjusted* MRI volumes (as % of whole-brain volume) for different MS courses
Mean (95% CI)
RR vs Sp RR vs SP SP vs PPRR, n  427 SP, n  140 PP, n  30
AWM-f 1.2 (1.0–1.4) 1.9 (1.6–2.2) 1.8 (1.2–2.5) 0.001 NS NS
gWM-f 34.2 (33.9–34.5) 32.8 (32.3–33.4) 33.1 (31.9–34.2) 0.001 NS NS
GM-f 51.4 (51.1–51.7) 50.0 (49.4–50.5) 50.7 (49.4–50.5) 0.001 NS NS
* Adjusted for age, sex, and education.
MS  multiple sclerosis; RR  relapsingremitting; SP  secondary progressive; PP  primary progressive; AWM-f  abnormal white
matter fraction; gWM-f  global white matter fraction; GM-f  gray matter fraction.
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Significant predictors of GM atrophy (GM-f) were again
EDSS score and age at disease onset. The relationship
between EDSS score and GM atrophy was as strong as
that between EDSS score and NAWM atrophy (a 1-point
increase in the EDSS score corresponded to a 0.54% de-
crease of GM-f; i.e., 6.5 cm3 for an average brain of 1,200
cm3). On the other hand, although significant, age at dis-
ease onset had both a low weight in predicting GM-f and
the lowest  coefficient, as a 0.15% decrease of GM-f was
found for each 5 years earlier of MS onset.
Table 3 shows the predictors of disability (as expressed
by the EDSS score), considering demographic, clinical, and
all MRI-related variables (which explain 56% of the vari-
ance of EDSS values in our MS cohort). MS disease course
was the strongest predictor of disability, followed by dis-
ease duration, age at disease onset, number of years of
schooling, and drug treatment. GM-f was the only MRI-
related variable significantly predicting level of disability.
None of the demographic, clinical, or MRI-related vari-
ables predicted relapse rate over the previous 2 years (full
model: F[15, 581]  1.0, p  0.458).
Figure 2 shows the adjusted mean value of each brain
volume fraction according to both EDSS and age at onset.
With regard to AWM-f, a lower lesion load (lower fraction
volume) was present among patients with EDSS of 3.5
compared with an EDSS score between 4.0 and 6.0 (p 
0.007). Patients with an age at disease onset before 20
years had the highest lesion load (highest AWM-f) with
respect to patients who were older at disease onset (p 
0.007 vs category 20 to 30 years; and p  0.001 vs category
30 years). With regard to GM-f, patients with EDSS
score of 3.5 displayed the lowest GM atrophy (highest
GM-f) compared with patients with higher EDSS score
(p  0.001 vs category 4.0 to 6.0 points; and p  0.006 vs
category 6.5 points). With regard to gWM-f, an inverse
pattern between EDSS and age at onset was found. In
Table 3 Predictors of disability (as expressed by EDSS score) by a forward stepwise regression model*
Predictors B (SE) 
Value
(95% CI of ) p Value
Intercept 6.7 (0.82)
MS course, vs PP 1.45 (0.09)
RR 0.52 (0.10) 0.49 (0.55, 0.43) 0.001
SP 0.05 (0.01) 0.16 (0.10, 0.21) 0.001
Disease duration, y 0.02 (0.01) 0.22 (0.16, 0.28) 0.001
Age at disease onset, y 0.07 (0.02) 0.12 (0.06, 0.18) 0.001
GM-f, % 0.05 (0.01) 0.12 (0.18, 0.07) 0.001
Years of school attendance 0.10 (0.16, 0.05) 0.001
Drug treatment,† vs never treated 0.03 (0.08)
IFN 0.11 (0.12) 0.01 (0.09, 0.07) 0.728
Other treatment 0.21 (0.14) 0.04 (0.05, 0.12) 0.369
IFN withdrawn 1.45 (0.09) 0.07 (0.02, 0.16) 0.129
* After seven steps, the multiple R2 of the model was 0.56 (F[9, 587]  84, p  0.001).
† One hundred seventy-five (29.3%) patients had never been treated, 316 (52.9%) were on IFN, 44 (7.4%) had withdrawn from IFN, and
62 (10.4%) were receiving other therapies (including glatiramer acetate, mitoxantrone, cyclophosphamide, and methotrexate).
EDSS  Expanded Disability Status Scale; MS  multiple sclerosis; SP  secondary progressive; RR  relapsingremitting; PP  pri-
mary progressive; GM-f  gray matter fraction; IFN  interferon.
Figure 2. Adjusted mean value (and
95% CI) of brain volume fractions ac-
cording to both Expanded Disability
Status Scale and age at onset (years).
AWM-f  abnormal white matter frac-
tion; GM-f  gray matter fraction;
gWM-f  global white matter
fraction.*p  0.01, **p  0.001 com-
parison vs the lower category.
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more detail, patients with an EDSS score of 3.5 showed
the lowest gWM atrophy (highest gWM-f) with respect to
patients with higher EDSS score (p  0.003 vs 4.0 to 6.0
category). Remarkably, a decreasing level of gWM atrophy
was present passing from cases with age at onset of 20
years to cases with a disease onset over 30 years (p 
0.001 for both comparisons).
Discussion. In this study, a fully automated MRI
technique was used in a large MS population to as-
sess both WM and GM atrophy and lesion load as
well as to investigate the intercorrelations between
MRI measurements of atrophy and lesion load and
the correlations between clinical and MRI data.
Some methodologic considerations need to be ad-
dressed. The method used provides AWM-f as a mea-
sure of lesion load based on the multiparametric and
fully automated approach, and it offers the advan-
tage of simultaneously measuring both lesion load
and WM and GM atrophy. We can therefore expect
that it would be highly sensitive at simultaneously
measuring lesion load and WM and GM atrophy. On
the other hand, we chose not to take into account the
possible contribution of additional important vari-
ables such as cervical spinal atrophy and postcon-
trast brain MRI, as neither would have been easily
quantifiable and both would have lengthened the
MRI examination and reading time.
Overall, compared with controls, patients with MS
had more atrophy of both WM (1.3%) and GM
(2.1%), and the burden of MS on brain volume,
with respect to an average brain of 1,200 cm3, can be
summarized by the appearance of 17 cm3 of AWM-f
and by the lack of about 16 cm3 of gWM-f and 25 cm3
and of GM-f. In more detail, patients with MS lost 17
cm3 of WM because of MRI-identifiable lesions
(AWM-f) and 16 cm3 because of volumetric measur-
able atrophy (gWM-f). Our results are in agreement
with previously published data,11 which described, in
26 patients with MS, a significant reduction of both
WM (approximately 4.9%) and GM fractions (ap-
proximately 2.8%). The slight differences in the
amount of WM and GM atrophy may be due to a
large difference in the number of patients studied,
although a difference in the segmentation methods
cannot be ruled out. In a small group of RR patients,
the loss of parenchymal volume in RR MS was pre-
dominantly confined to WM.14 With use of the same
segmentation method in 50 patients with RR MS, a
significant reduction of GM-f was found, whereas
WM-f was not significantly different between pa-
tients and control subjects.13 The lack of significant
WM atrophy may be due to the small sample of RR
patients studied.13 A T1-weighted segmentation
method was used to separate segmented GM into
neocortical and non-neocortical in 90 RR and PP pa-
tients, and a significant reduction of neocortical GM
was found in both groups of patients.12 A different
approach to the assessment of GM atrophy was re-
cently described by a novel method of automated
surface reconstruction to measure cortical thickness,
and a significant focal and overall cortical thinning
in 20 patients with MS was found.20 Compared with
previous studies, we produced more comprehensive
evidence that there is significant atrophy of both GM
and WM in patients with MS, thus confirming the
pathologic evidence1-4 of GM involvement in MS.
Among the studies based on automated MR seg-
mentation methods, only one12 assessed differences
between patients with different disease courses and
found no significant differences in neocortical GM
between RR and PP patients. In the current study,
we showed that SP patients, with respect to RR ones,
have significantly more atrophy of both GM and
WM, thus suggesting that brain atrophy may be rel-
evant in determining the course of the disease and
eventually disease progression. No differences were
found in the small group of PP patients.
So far, the intercorrelations between lesion load
and WM and GM have been only partially addressed.
In 26 patients with MS, T1- and T2-weighted lesion
volumes were inversely related to GM-f but not to
WM-f.11 In 50 RR patients, AWM-f was inversely cor-
related to GM-f but not to global WM-f.13 In patients
with RR MS, a significant correlation between neo-
cortical atrophy and T2 lesion volume was found,
whereas no correlation was found in PP patients.12 A
significant correlation between thinning of the cere-
bral cortex and T1-T2 lesion volume was found in 20
patients with MS.20 We showed that lesion load is
significantly correlated with both GM and WM atro-
phy; however, a significantly stronger relationship
was found with GM-f than with gWM-f. These re-
sults support the hypothesis that GM atrophy is
heavily dependent on lesion load, possibly owing to
retrograde degeneration of GM neurons secondary to
fibers traversing WM lesions,21,22 although we cannot
ignore the possibility of both discrete and diffuse
independent GM lesions that may be undetectable by
conventional MRI.2,4
Measurements of MRI-segmented volumes were
significantly correlated to disability and age at dis-
ease onset and, to a lesser extent, drug treatment. So
far, the studies addressing the relationship between
MRI and disability have reported conflicting results,
and this has been attributed to the poor sensitivity of
the EDSS, although, more recently, functional MRI
studies23 suggested that the possible impact of plas-
ticity may play a key role in determining the result-
ing disability. Significant correlations between
disability and WM and GM atrophy were not found
in 30 patients with RR MS.14 A significant correla-
tion between neocortical atrophy and EDSS was de-
scribed in both RR and PP patients, whereas the
correlation with disease duration was found only in
RR patients.12 A significant correlation between GM
atrophy and EDSS was reported, but there was no
correlation between WM atrophy and disease dura-
tion.11 We produced very strong evidence that lesion
load and both WM and GM atrophy are significantly
correlated with disability. The existence of a close
relationship between GM atrophy and disability is
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further supported by the significant association
found in the analysis of predictors of disability. This
correlation supports the role that GM involvement
may play in the pathogenesis of MS and urges us to
focus on neurodegeneration as a key feature of MS.
The correlation with age at disease onset suggests
that the younger the age at disease onset, the worse
the lesion load and brain atrophy (especially of WM)
will be. These data suggest that brain atrophy is
related to what happens at the very beginning of the
disease rather than during the disease course. This
hypothesis is in accordance with previous reports.
Global brain atrophy (as derived from the parenchy-
mal fraction) and central atrophy (as derived from
the ventricular fraction) were longitudinally mea-
sured in 83 patients with MS at an interval of 2 to 4
years.24 The main observations were that clinical
characteristics (such as duration of symptoms and
EDSS) did not predict the variance in the rate of
global or central atrophy, whereas the rate of central
atrophy was significantly higher in younger patients.
Twenty-eight patients with MS were followed for up
to 14 years after the first onset of symptoms,25 and
lesion load in the first 5 years was more closely cor-
related with disease-related brain atrophy at 14
years than were later changes in lesion load. Fur-
thermore, in a cohort of patients with RR MS, lesion
load (as derived from the average number of total
and new gadolinium-enhanced lesions) decreased
significantly with increasing patient age, indepen-
dently of disease duration and relapse rate.26
In line with the use of IFN in clinical practice, in
a cross-sectional survey, it was found that patients
assigned to treatment with IFN had a higher lesion
load (adjusted mean of 1.6%; 95% CI 1.4 to 1.7) than
those who had never received this drug because a
watchful-waiting approach had been preferred (1.2%;
95% CI 1.0 to 1.5).
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